

## Hematology

No	Tumor Site	protocol	Study title	計畫案中文名稱	Web site	備註
1	Allogenic HCT	0113-CL-1004	A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)	一項隨機分配、雙盲、安慰劑對照第3期試驗，以評估將 ASP0113 治療疫苗用於接受異體造血細胞移植 (Hematopoietic Cell Transplant; HCT) 的巨細胞病毒 (Cytomegalovirus; CMV) 血清反應陽性受贈者的保護療效及安全性	<a href="https://clinicaltrials.gov/ct2/show/NCT01877655?term=ASP0113&amp;rank=2">https://clinicaltrials.gov/ct2/show/NCT01877655?term=ASP0113&amp;rank=2</a>	如有疑問請掛 本科醫師門診 詢問。
2	Retuximab-Relapse iNHL	BAY-17067	Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)	一項針對復發性和緩性B細胞非何杰金氏淋巴瘤(iNHL)患者，評估copanlisib併用rituximab的療效與安全性的第三期、隨機分配、雙盲、安慰劑對照試驗－CHRONOS-3	<a href="https://clinicaltrials.gov/ct2/show/NCT02367040?term=COPANLISIB&amp;rank=4">https://clinicaltrials.gov/ct2/show/NCT02367040?term=COPANLISIB&amp;rank=4</a>	
3	Retuximab-RefractoryiNHL	BAY-17322	Phase III Copanlisib in Rituximab-refractory iNHL (CHRONOS-2)	一項針對rituximab難治型和緩性非何杰金氏淋巴瘤(iNHL)病患比較copanlisib與安慰劑的隨機、雙盲、第3期試驗－CHRONOS-2	<a href="https://clinicaltrials.gov/ct2/show/NCT02369016?term=COPANLISIB&amp;rank=12">https://clinicaltrials.gov/ct2/show/NCT02369016?term=COPANLISIB&amp;rank=12</a>	
4	PMF/ Post PV/ET	GS-US-352-0101	Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)	計畫名稱：一項第3期、隨機、雙盲有效藥對照研究，用於評估 Momelotinib 對比 Ruxolitinib 對治療患有原發性骨髓纖維化 (PMF) 或真性紅細胞增生後或原發性血小板增生後骨髓纖維化(Post-PV/ET MF) 的患者的療效	<a href="https://clinicaltrials.gov/ct2/show/NCT01969838?term=PMF&amp;rank=17">https://clinicaltrials.gov/ct2/show/NCT01969838?term=PMF&amp;rank=17</a>	

5	AML		<p>A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice(TC) in Adult with Previously Untreated Acute Myeloid Leukemia(AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy</p>	<p>一項多中心、開放標記、隨機分配的第三期臨床試驗，針對患有急性骨髓性白血病(AML)、之前未治療過，且不適合接受密集緩解誘導式化療的成人患者，評估SGI-110相較於選擇治療(TC)之療效</p>			
6	AML		<p>A phase 3, Randomized, Double-blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Best Supportive Care as maintenance Therapy in Subject with Acute Myeloid Leukemia(AML) in Complete Remission</p>	<p>一項隨機分配、雙盲、安慰劑對照的第3期試驗，針對急性骨髓性白血病完全緩解的受試者，探討口服azacitidine 加上最佳支持性照護相較於最佳支持性照護，做為維持性治療的療效與安全性</p>		<p>如有疑問 請掛本科 醫師門診 詢問。</p>	
7	urothelial carcinoma		<p>Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma.</p>	<p>比較Vinflunine與Gemcitabine的合併療法和Gemcitabine與Carboplatin的合併療法治療不適合使用Cisplatin治療之晚期或轉移性泌尿上皮癌病患的隨機分配第三期臨床試驗</p>			

## ONCOLOGY

No	Site	protocol	study title		web site	備註
1	HNSCC	MK37475-048	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	一項以Pembrolizumab (MK-3475) 作為復發性/轉移性頭頸部鱗狀細胞癌第一線治療的第三期臨床試驗	<a href="https://clinicaltrials.gov/ct2/show/NCT02358031?term=mk3475-048&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02358031?term=mk3475-048&amp;rank=1</a>	如有疑問請掛本科醫師門診詢問。
2	Phase IV Melanoma+HC V/ HBV carrier	CA184-414	Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan (Yervoy RMP)	以益伏注射劑(Yervoy®, Ipilimumab)治療台灣受B型與/或C型肝炎病毒感染的晚期惡性黑色素瘤病患之藥物安全警戒監測研究	<a href="https://clinicaltrials.gov/ct2/show/NCT02402699?term=ca184-414&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02402699?term=ca184-414&amp;rank=1</a>	
3	Esophageal cancer		A Multicenter, Randomized, Open-label Study in Patients with esophageal Cancer refractory or intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs	一項多中心、隨機分配、開放性、對Fuoropyrimidine 及含鉑藥物合併治療反應不佳或無法耐受的食道癌患者之研究		
4	Head and Neck Cancer		A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients	一項針對第一線治療復發性或轉移性頭頸部鱗狀細胞癌患者(SCCHN)，評估MEDI4736 與 Tremelimumab 合併療法相較於標準照護治療的第三期、隨機分配、開放標示、多中心之全球試驗		
5	HCC	97-07- 07 (TPEVGH)	Valproic acid and hydralazine-modulated gemcitabine and cisplatin followed by doxorubicin and dacarbazine in advanced hepatocellular carcinoma.	A phase II clinical trial.	Patient recruitment closed	

\_\_\_\_\_

\_\_\_\_\_





|